Last reviewed · How we verify
Etripamil NS
Etripamil is a rapid-onset, short-acting calcium channel blocker administered as a nasal spray that slows heart rate and reduces blood pressure by blocking L-type calcium channels in cardiac and vascular tissue.
Etripamil is a rapid-onset, short-acting calcium channel blocker administered as a nasal spray that slows heart rate and reduces blood pressure by blocking L-type calcium channels in cardiac and vascular tissue. Used for Acute conversion of supraventricular tachycardia to normal sinus rhythm.
At a glance
| Generic name | Etripamil NS |
|---|---|
| Also known as | MSP-2017 |
| Sponsor | Milestone Pharmaceuticals Inc. |
| Drug class | Calcium channel blocker (non-dihydropyridine) |
| Target | L-type calcium channel |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Etripamil works by inhibiting L-type calcium channels in the sinoatrial (SA) node and atrioventricular (AV) node of the heart, which slows conduction and reduces heart rate. Its intranasal formulation allows for rapid systemic absorption and quick onset of action, making it suitable for acute conversion of supraventricular tachycardia. The drug's short half-life and rapid offset provide a favorable safety profile with quick reversibility if adverse effects occur.
Approved indications
- Acute conversion of supraventricular tachycardia to normal sinus rhythm
Common side effects
- Nasal discomfort or irritation
- Headache
- Dizziness
- Hypotension
- Bradycardia
Key clinical trials
- ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3 (PHASE3)
- The NODE-202 Study (Study of Etripamil Nasal Spray in Pediatric Patients) (PHASE2)
- Etripamil Nasal Spray in Patients With Paroxysmal Supraventricular Tachycardia (PHASE3)
- Efficacy and Safety Study of Etripamil Nasal Spray Self-Administration for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (PHASE3)
- Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (PSVT). NODE-302 (PHASE3)
- ReVeRA-201: Etripamil in Atrial Fibrillation, Phase 2 (PHASE2)
- Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia. NODE-303 (PHASE3)
- A Study of Etripamil in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Etripamil NS CI brief — competitive landscape report
- Etripamil NS updates RSS · CI watch RSS
- Milestone Pharmaceuticals Inc. portfolio CI